• Exploration of Drug Science

    eISSN: 2836-7677
    EiC: Fernando Albericio, PhD, Universidad de Barcelona and University of KwaZulu-Natal
    Frequency: Bimonthly
    APC: No Article Processing Charge
    Publishing Model: Open Access
    Peer Review Model: Single Blind
    Indexing & Archiving: Portico
    Follow the journal:
    Follow the journal:
    Articles
    Open Access
    Original Article
    Heterogeneous graph convolutional neural network for protein-ligand scoring
    Aim: Drug discovery is a long process, often taking decades of research endeavors. It is still an active area of research in both academic and industrial sectors with efforts on reducing time and [...] Read more.
    Kevin Crampon ... Luiz Angelo Steffenel
    Published: April 30, 2023 Explor Drug Sci. 2023;1:126–139
    DOI: https://doi.org/10.37349/eds.2023.00010
    This article belongs to the special issue Machine Learning for Drug Science
    View:146
    Download:17
    Times Cited: 0
    Open Access
    Review
    Focused ultrasound for treatment of peripheral brain tumors
    Malignant brain tumors are the leading cause of cancer-related death in children and remain a significant cause of morbidity and mortality throughout all demographics. Central nervous system (CNS) t [...] Read more.
    Phillip Mitchell Johansen ... Brandon Lucke-Wold
    Published: April 28, 2023 Explor Drug Sci. 2023;1:107–125
    DOI: https://doi.org/10.37349/eds.2023.00009
    View:193
    Download:14
    Times Cited: 0
    Open Access
    Review
    Nano theranostics involved in bladder cancer treatment
    Bladder cancer (BC) is a complex disease with multiple clinical manifestations and treatment challenges, and current standard-of-care therapies remain limited and unfavorable. Theranostics, the inte [...] Read more.
    Kunpeng Liu ... Qingsong Yu
    Published: April 28, 2023 Explor Drug Sci. 2023;1:81–106
    DOI: https://doi.org/10.37349/eds.2023.00008
    This article belongs to the special issue Emerging Nanomedicine Technologies for Enhanced Cancer Theranostics
    View:182
    Download:8
    Times Cited: 0
    Open Access
    Editorial
    Machine learning for drug science
    Walter F. de Azevedo Jr.
    Published: April 16, 2023 Explor Drug Sci. 2023;1:77–80
    DOI: https://doi.org/10.37349/eds.2023.00007
    This article belongs to the special issue Machine Learning for Drug Science
    View:134
    Download:9
    Times Cited: 0
    Open Access
    Original Article
    Levistolide A and periplogenin inhibit the growth of gastric cancer cells in vitro and in vivo
    Aim: In the present study, the natural products levistolide A (LA) and periplogenin (PPG) were studied for their growth inhibitory effects on the development of gastric cancer cells in vitro and,  [...] Read more.
    Jia Li Guo ... Ji Zhong Zhao
    Published: March 30, 2023 Explor Drug Sci. 2023;1:64–76
    DOI: https://doi.org/10.37349/eds.2023.00006
    This article belongs to the special issue Exploring Potential Drugs from Natural Products
    View:240
    Download:13
    Times Cited: 0
    Open Access
    Systematic Review
    Utilizing the Ethereum blockchain for retrieving and archiving augmented reality surgical navigation data
    Aim: Conventional techniques to share and archive spinal imaging data raise issues with trust and security, with novel approaches being more greatly considered. Ethereum smart contracts present o [...] Read more.
    Sai Batchu ... Brandon Lucke-Wold
    Published: February 28, 2023 Explor Drug Sci. 2023;1:55–63
    DOI: https://doi.org/10.37349/eds.2023.00005
    View:254
    Download:15
    Times Cited: 0
    Open Access
    Editorial
    Drug discovery: a multifactorial ecosystem
    Fernando Albericio
    Published: January 01, 2023 Explor Drug Sci. 2023;1:1–5
    DOI: https://doi.org/10.37349/eds.2022.00001
    View:602
    Download:52
    Times Cited: 0
    Open Access
    Review
    Essential functions, syntheses and detection of sialyl Lewis X on glycoproteins
    It is widely acknowledged that sialyl Lewis X (sLeX), the composition and linkage of which are N-acetylneuraminic acid (Neu5Ac) α2-3 galactose (Gal) β1-4 [fucose (Fuc) α1-3] N-acetylglucosamine, is usually attached to the cell  [...] Read more.
    Qiushi Chen ... Xuechen Li
    Published: February 28, 2023 Explor Drug Sci. 2023;1:31–54
    DOI: https://doi.org/10.37349/eds.2023.00004
    This article belongs to the special issue Bioactive Peptides discovery and development
    View:355
    Download:23
    Times Cited: 0
    Open Access
    Systematic Review
    Utilizing the Ethereum blockchain for retrieving and archiving augmented reality surgical navigation data
    Aim: Conventional techniques to share and archive spinal imaging data raise issues with trust and security, with novel approaches being more greatly considered. Ethereum smart contracts present o [...] Read more.
    Sai Batchu ... Brandon Lucke-Wold
    Published: February 28, 2023 Explor Drug Sci. 2023;1:55–63
    DOI: https://doi.org/10.37349/eds.2023.00005
    View:254
    Download:15
    Times Cited: 0
    Open Access
    Original Article
    Levistolide A and periplogenin inhibit the growth of gastric cancer cells in vitro and in vivo
    Aim: In the present study, the natural products levistolide A (LA) and periplogenin (PPG) were studied for their growth inhibitory effects on the development of gastric cancer cells in vitro and,  [...] Read more.
    Jia Li Guo ... Ji Zhong Zhao
    Published: March 30, 2023 Explor Drug Sci. 2023;1:64–76
    DOI: https://doi.org/10.37349/eds.2023.00006
    This article belongs to the special issue Exploring Potential Drugs from Natural Products
    View:240
    Download:13
    Times Cited: 0
    Open Access
    Original Article
    Surface functionalized mesoporous polydopamine nanocomposites for killing tumor cells through collaborative chemo/photothermal/chemodynamic treatment
    Aim: The development of a collaborative strategy with improved efficacy holds great promise in tumor treatment. This study aims to develop an effective collaborative strategy based on functionalized mesoporous polydopamine (MPDA)  [...] Read more.
    Yi Ouyang ... Hui Liu
    Published: February 27, 2023 Explor Drug Sci. 2023;1:18–30
    DOI: https://doi.org/10.37349/eds.2023.00003
    This article belongs to the special issue Emerging Nanomedicine Technologies for Enhanced Cancer Theranostics
    View:219
    Download:14
    Times Cited: 0
    Open Access
    Review
    Focused ultrasound for treatment of peripheral brain tumors
    Malignant brain tumors are the leading cause of cancer-related death in children and remain a significant cause of morbidity and mortality throughout all demographics. Central nervous system (CNS) t [...] Read more.
    Phillip Mitchell Johansen ... Brandon Lucke-Wold
    Published: April 28, 2023 Explor Drug Sci. 2023;1:107–125
    DOI: https://doi.org/10.37349/eds.2023.00009
    View:193
    Download:14
    Times Cited: 0
    Open Access
    Editorial
    Drug discovery: a multifactorial ecosystem
    Fernando Albericio
    Published: January 01, 2023 Explor Drug Sci. 2023;1:1–5
    DOI: https://doi.org/10.37349/eds.2022.00001
    View:602
    Download:52
    Times Cited: 0
    Open Access
    Review
    Essential functions, syntheses and detection of sialyl Lewis X on glycoproteins
    It is widely acknowledged that sialyl Lewis X (sLeX), the composition and linkage of which are N-acetylneuraminic acid (Neu5Ac) α2-3 galactose (Gal) β1-4 [fucose (Fuc) α1-3] N-acetylglucosamine, is usually attached to the cell  [...] Read more.
    Qiushi Chen ... Xuechen Li
    Published: February 28, 2023 Explor Drug Sci. 2023;1:31–54
    DOI: https://doi.org/10.37349/eds.2023.00004
    This article belongs to the special issue Bioactive Peptides discovery and development
    View:355
    Download:23
    Times Cited: 0
    Open Access
    Original Article
    Heterogeneous graph convolutional neural network for protein-ligand scoring
    Aim: Drug discovery is a long process, often taking decades of research endeavors. It is still an active area of research in both academic and industrial sectors with efforts on reducing time and [...] Read more.
    Kevin Crampon ... Luiz Angelo Steffenel
    Published: April 30, 2023 Explor Drug Sci. 2023;1:126–139
    DOI: https://doi.org/10.37349/eds.2023.00010
    This article belongs to the special issue Machine Learning for Drug Science
    View:146
    Download:17
    Times Cited: 0
    Open Access
    Original Article
    Convenient estimation of oxytetracycline and polymyxin B by a novel high-performance liquid chromatography method: development and validation
    Aim: The aim of this research work was to develop a validated reversed-phase (RP)-high-performance liquid chromatography (HPLC) method for simultaneous estimation of oxytetracycline (OXY) and pol [...] Read more.
    Tanu Chaudhary ... Dilpreet Singh
    Published: February 24, 2023 Explor Drug Sci. 2023;1:6–17
    DOI: https://doi.org/10.37349/eds.2023.00002
    View:151
    Download:16
    Times Cited: 0
    Open Access
    Systematic Review
    Utilizing the Ethereum blockchain for retrieving and archiving augmented reality surgical navigation data
    Aim: Conventional techniques to share and archive spinal imaging data raise issues with trust and security, with novel approaches being more greatly considered. Ethereum smart contracts present o [...] Read more.
    Sai Batchu ... Brandon Lucke-Wold
    Published: February 28, 2023 Explor Drug Sci. 2023;1:55–63
    DOI: https://doi.org/10.37349/eds.2023.00005
    View:254
    Download:15
    Times Cited: 0
    Open Access
    Original Article
    Surface functionalized mesoporous polydopamine nanocomposites for killing tumor cells through collaborative chemo/photothermal/chemodynamic treatment
    Aim: The development of a collaborative strategy with improved efficacy holds great promise in tumor treatment. This study aims to develop an effective collaborative strategy based on functionalized mesoporous polydopamine (MPDA)  [...] Read more.
    Yi Ouyang ... Hui Liu
    Published: February 27, 2023 Explor Drug Sci. 2023;1:18–30
    DOI: https://doi.org/10.37349/eds.2023.00003
    This article belongs to the special issue Emerging Nanomedicine Technologies for Enhanced Cancer Theranostics
    View:219
    Download:14
    Times Cited: 0
    Open Access
    Editorial
    Drug discovery: a multifactorial ecosystem
    Fernando Albericio
    Published: January 01, 2023 Explor Drug Sci. 2023;1:1–5
    DOI: https://doi.org/10.37349/eds.2022.00001
    View:602
    Download:52
    Times Cited: 0
    Open Access
    Original Article
    Convenient estimation of oxytetracycline and polymyxin B by a novel high-performance liquid chromatography method: development and validation
    Aim: The aim of this research work was to develop a validated reversed-phase (RP)-high-performance liquid chromatography (HPLC) method for simultaneous estimation of oxytetracycline (OXY) and pol [...] Read more.
    Tanu Chaudhary ... Dilpreet Singh
    Published: February 24, 2023 Explor Drug Sci. 2023;1:6–17
    DOI: https://doi.org/10.37349/eds.2023.00002
    View:151
    Download:16
    Times Cited: 0
    Open Access
    Original Article
    Surface functionalized mesoporous polydopamine nanocomposites for killing tumor cells through collaborative chemo/photothermal/chemodynamic treatment
    Aim: The development of a collaborative strategy with improved efficacy holds great promise in tumor treatment. This study aims to develop an effective collaborative strategy based on functionalized mesoporous polydopamine (MPDA)  [...] Read more.
    Yi Ouyang ... Hui Liu
    Published: February 27, 2023 Explor Drug Sci. 2023;1:18–30
    DOI: https://doi.org/10.37349/eds.2023.00003
    This article belongs to the special issue Emerging Nanomedicine Technologies for Enhanced Cancer Theranostics
    View:219
    Download:14
    Times Cited: 0
    Open Access
    Review
    Essential functions, syntheses and detection of sialyl Lewis X on glycoproteins
    It is widely acknowledged that sialyl Lewis X (sLeX), the composition and linkage of which are N-acetylneuraminic acid (Neu5Ac) α2-3 galactose (Gal) β1-4 [fucose (Fuc) α1-3] N-acetylglucosamine, is usually attached to the cell  [...] Read more.
    Qiushi Chen ... Xuechen Li
    Published: February 28, 2023 Explor Drug Sci. 2023;1:31–54
    DOI: https://doi.org/10.37349/eds.2023.00004
    This article belongs to the special issue Bioactive Peptides discovery and development
    View:355
    Download:23
    Times Cited: 0
    Open Access
    Systematic Review
    Utilizing the Ethereum blockchain for retrieving and archiving augmented reality surgical navigation data
    Aim: Conventional techniques to share and archive spinal imaging data raise issues with trust and security, with novel approaches being more greatly considered. Ethereum smart contracts present o [...] Read more.
    Sai Batchu ... Brandon Lucke-Wold
    Published: February 28, 2023 Explor Drug Sci. 2023;1:55–63
    DOI: https://doi.org/10.37349/eds.2023.00005
    View:254
    Download:15
    Times Cited: 0
    Open Access
    Original Article
    Levistolide A and periplogenin inhibit the growth of gastric cancer cells in vitro and in vivo
    Aim: In the present study, the natural products levistolide A (LA) and periplogenin (PPG) were studied for their growth inhibitory effects on the development of gastric cancer cells in vitro and,  [...] Read more.
    Jia Li Guo ... Ji Zhong Zhao
    Published: March 30, 2023 Explor Drug Sci. 2023;1:64–76
    DOI: https://doi.org/10.37349/eds.2023.00006
    This article belongs to the special issue Exploring Potential Drugs from Natural Products
    View:240
    Download:13
    Times Cited: 0
    Special Issues
    From the Editor-in-Chief
    The journey from the idea in the laboratory to the drug on the market is possibly the most exciting scientific process and, at the same time, the one with the most significant impact from both social and economic point of view. On the one hand, a new drug helps restore health and improves well-being, even saving lives, but it requires many years of work (an average of 15 years) and a large investment. Exploration of Drug Science (EDS) was born with the idea of covering all the steps of this often magical process, from the discovery itself, the preclinical phase, to the clinical phase. As the new Editor-in-Chief of EDS, I would like to invite colleagues to use our platform to share their latest findings with the scientific committee.
    Fernando Albericio
    Editor-in-Chief of Exploration of Drug Science